Metraipolis › archive › dc_3d52d4e565f5

Cost-effectiveness of rilertinib versus osimertinib in second-line treatment in EGFR T790M resistance mutation advanced non-small cell lung cancer in China — Europe PMC PMID:41142240

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41142240
DOI
10.3389/fphar.2025.1628024
License (as archived)
solo-consultazione
Archived
2026-11-09T11:30:13.542Z
SHA-256 of the archived text
3d9735ddbd9cbbf67a22747785d7debc463626b82af6e50eb11838fec45a5a12
Stable URL of this page
https://metraipolis.com/documento/dc_3d52d4e565f5

How to cite

Cost-effectiveness of rilertinib versus osimertinib in second-line treatment in EGFR T790M resistance mutation advanced non-small cell lung cancer in China — Europe PMC PMID:41142240 — Europe PMC (en), https://europepmc.org/article/MED/41142240 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_3d52d4e565f5 (Metraipolis archive dc_3d52d4e565f5, sha256 3d9735ddbd9cbbf67a22747785d7debc463626b82af6e50eb11838fec45a5a12)
BibTeX
@misc{dc3d52d4e565f5,
  title = {Cost-effectiveness of rilertinib versus osimertinib in second-line treatment in EGFR T790M resistance mutation advanced non-small cell lung cancer in China — Europe PMC PMID:41142240},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41142240},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_3d52d4e565f5; sha256 3d9735ddbd9cbbf67a22747785d7debc463626b82af6e50eb11838fec45a5a12},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41142240. Agents can read the archived copy with the MCP tool read_document.